Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 21, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.176, Tarlatamab-dlle (Imdelltra™) for intravenous use

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Apr 21, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new Medicare Advantage policy MA08.176 has been established for Tarlatamab-dlle (Imdelltra™) for intravenous use, effective April 21, 2025. This is a new pharmacy policy that will likely establish coverage criteria and billing requirements for this medication.

Action Required

Action needed

Before April 21, 2025: Billing team must review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Tarlatamab-dlle (Imdelltra™). Update billing system and staff training as needed once complete policy details are available.

Related policy hubs

Independence Blue Cross policies Oncology Hematology